Augmenix Inc. said this week that it launched its SpaceOar hydrogel device in Israel.
The Bedford, Mass.-based company’s absorbable prostate-rectum spacer is designed to reduce rectal injury during prostate radiotherapy.
“We are excited to offer our patients this new, innovative technology to significantly reduce risks of prostate cancer radiotherapy,” Dr. Zvi Symon, from the Chaim Sheba Medical Center, said in prepared remarks. “SpaceOar hydrogel will provide meaningful long-term benefits, improving overall quality of life for our patients.”
“We are extremely pleased to bring our innovative SpaceOar hydrogel to physicians and patients in Israel,” CEO John Pedersen added. “Our growing body of clinical evidence demonstrates that SpaceOar hydrogel significantly reduces the risk of rectal and urinary toxicities and loss of sexual function associated with prostate cancer radiotherapy. SpaceOar hydrogel is making a significant difference in the lives of men around the world.”
In January, the company touted data showing that patients treated with SpaceOar prior to prostate cancer radiotherapy had significant rectal, urinary and sexual benefit 3-years following treatment.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.